Janssen Biotech, Inc.
Clinical trials sponsored by Janssen Biotech, Inc., explained in plain language.
A subsidiary of Johnson & Johnson, developing biotech therapies across multiple disease areas.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Simponi under the microscope: new registry tracks Long-Term risks in ulcerative colitis patients Results expected Dec 2026 (estimated)